This single arm study will assess the efficacy and safety of Xeloda + oxaliplatin when given as first line treatment for patients with metastatic nasopharyngeal cancer. Patients will receive Xeloda (1000mg/m2 bid orally from day 1 to day 14, followed by a rest period of 7 days) plus oxaliplatin (130mg/m2 iv infusion on day 1 of each 21 day cycle) for 6-8 cycles. The anticipated time on study treatment is until disease progression, and the target sample size is <100 individuals.

Inclusion Criteria:

• adult patients, 18-75 years of age;
• history of nasopharyngeal cancer and distant metastases;
• no previous chemotherapy in past 6 months;
• recovery from previous radiotherapy;
• ability to swallow and retain oral medication.

Exclusion Criteria:

• previous cytotoxic chemotherapy;
• radiotherapy within 4 weeks of treatment start;
• history of another malignancy within the last 5 years;
• clinically significant cardiac disease.